<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Adenoviral-Vector-Gene-Therapy on Bioecon</title><link>https://en.bioecon.ru/technologies/adenoviral-vector-gene-therapy/</link><description>Recent content in Adenoviral-Vector-Gene-Therapy on Bioecon</description><generator>Hugo</generator><language>en-US</language><lastBuildDate>Fri, 18 Sep 2026 22:32:37 +0700</lastBuildDate><atom:link href="https://en.bioecon.ru/technologies/adenoviral-vector-gene-therapy/index.xml" rel="self" type="application/rss+xml"/><item><title>Adenoviral vector gene therapy</title><link>https://en.bioecon.ru/technology/adenoviral-vector-gene-therapy/</link><pubDate>Fri, 18 Sep 2026 14:00:00 +0000</pubDate><guid>https://en.bioecon.ru/technology/adenoviral-vector-gene-therapy/</guid><description>Replication-defective adenoviral vectors that deliver vaccine antigens and therapeutic genes at industrial scale — platform families validated in pandemic trials, suspension bioreactors to 2,000 L, and the plasmid-to-vector GMP chain that feeds them. The table carries four vendors whose dossier ledgers carry full source trails.</description></item></channel></rss>